 SAN DIEGO, April 01, 2022 GLOBE NEWSWIRE -- Longboard Pharmaceuticals, Inc. Nasdaq: LBPH, a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that single ascending dose and multiple ascending dose data from the Phase 1 study evaluating LP352 in healthy volunteers will be presented at the American Academy of Neurology AAN Annual Meeting being held in person April 27, 2022, in Seattle, WA, and virtually April 2426, 2022. 